Impact of CYP4F2 rs2108622 on the Stable Warfarin Dose in an Admixed Patient Cohort
作者： J A Perini , C J Struchiner , E Silva-Assunção , G Suarez-Kurtz
关键词: Anticoagulant 、 Cohort study 、 Warfarin 、 Retrospective cohort study 、 Pediatrics 、 CYP4F2 、 Cohort 、 Medicine 、 Genotyping 、 Polymorphism (computer science)
摘要: There is controversy regarding the association between CYP4F2 rs2108622 (V33M) polymorphism and warfarin dose requirement in white patients, there are no data for nonwhite populations. We observed self-identified white, black, or "intermediate" Brazilian patients (n = 370). The addition of genotype as a variable has only marginal effect on predictive power dosing algorithm derived from this patient cohort. conclude that prospective genotyping not justified Brazilians who potential candidates therapy.
nature.com
sci-hub.se 参考文章(15)
TE Klein, RB Altman, Niclas Eriksson, BF Gage, SE Kimmel, MT Lee, NA Limdi, D Page, DM Roden, MJ Wagner, MD Caldwell, JA Johnson, YT Chen, MS Wen, Y Caraco, I Achache, S Blotnick, M Muszkat, JG Shin, HS Kim, G Suarez-Kurtz, JA Perini, E Silva-Assuncao, JL Anderson, BD Horne, JF Carlquist, RL Berg, JK Burmester, BC Goh, SC Lee, F Kamali, E Sconce, AK Daly, AH Wu, TY Langaee, H Feng, L Cavallari, K Momary, M Pirmohamed, A Jorgensen, CH Toh, P Williamson, H McLeod, JP Evans, KE Weck, C Brensinger, Y Nakamura, T Mushiroda, D Veenstra, L Meckley, MJ Rieder, AE Rettie, M Wadelius, H Melhus, CM Stein, U Schwartz, D Kurnik, E Deych, P Lenzini, C Eby, LY Chen, P Deloukas, A Motsinger-Reif, H Sagreiya, BS Srinivasan, E Lantz, T Chang, M Ritchie, LS Lu, Estimation of the warfarin dose with clinical and pharmacogenetic data The New England Journal of Medicine. ,vol. 360, pp. 753- 764 ,(2009) , 10.1056/NEJMOA0809329
Michael D. Caldwell, Tarif Awad, Julie A. Johnson, Brian F. Gage, Mat Falkowski, Paul Gardina, Jason Hubbard, Yaron Turpaz, Taimour Y. Langaee, Charles Eby, Cristi R. King, Amy Brower, John R. Schmelzer, Ingrid Glurich, Humberto J. Vidaillet, Steven H. Yale, Kai Qi Zhang, Richard L. Berg, James K. Burmester, CYP4F2 genetic variant alters required warfarin dose. Blood. ,vol. 111, pp. 4106- 4112 ,(2008) , 10.1182/BLOOD-2007-11-122010
Mateus Fuchshuber-Moraes, Jamila A Perini, Dieter Rosskopf, Guilherme Suarez-Kurtz, None, Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin European Journal of Clinical Pharmacology. ,vol. 65, pp. 789- 793 ,(2009) , 10.1007/S00228-009-0651-6
JA Perini, CJ Struchiner, E Silva-Assunção, ISC Santana, F Rangel, EB Ojopi, E Dias-Neto, G Suarez-Kurtz, Pharmacogenetics of Warfarin: Development of a Dosing Algorithm for Brazilian Patients Clinical Pharmacology & Therapeutics. ,vol. 84, pp. 722- 728 ,(2008) , 10.1038/CLPT.2008.166
Fumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, Chris Barnes, Niclas Eriksson, Nicole Soranzo, Pamela Whittaker, Venkatesh Ranganath, Vasudev Kumanduri, William McLaren, Lennart Holm, Jonatan Lindh, Anders Rane, Mia Wadelius, Panos Deloukas, A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose PLOS Genetics. ,vol. 5, pp. 1000433- ,(2009) , 10.1371/JOURNAL.PGEN.1000433
Jieying Eunice Zhang, Andrea L. Jorgensen, Ana Alfirevic, Paula R. Williamson, Cheng H. Toh, Brian Kevin Park, Munir Pirmohamed, Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy Pharmacogenetics and Genomics. ,vol. 19, pp. 781- 789 ,(2009) , 10.1097/FPC.0B013E3283311347
Gregory M. Cooper, Julie A. Johnson, Taimour Y. Langaee, Hua Feng, Ian B. Stanaway, Ute I. Schwarz, Marylyn D. Ritchie, C. Michael Stein, Dan M. Roden, Joshua D. Smith, David L. Veenstra, Allan E. Rettie, Mark J. Rieder, A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose Blood. ,vol. 112, pp. 1022- 1027 ,(2008) , 10.1182/BLOOD-2008-01-134247
Franz Faul, Edgar Erdfelder, Axel Buchner, Albert-Georg Lang, Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behavior Research Methods. ,vol. 41, pp. 1149- 1160 ,(2009) , 10.3758/BRM.41.4.1149
Daniel W Nebert, Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. European Journal of Pharmacology. ,vol. 410, pp. 107- 120 ,(2000) , 10.1016/S0014-2999(00)00809-8
Matthew G. McDonald, Mark J. Rieder, Mariko Nakano, Clara K. Hsia, Allan E. Rettie, CYP4F2 IS A VITAMIN K1 OXIDASE: AN EXPLANATION FOR ALTERED WARFARIN DOSE IN CARRIERS OF THE V433M VARIANT Molecular Pharmacology. ,vol. 75, pp. 1337- 1346 ,(2009) , 10.1124/MOL.109.054833